Intermediate Uveitis: A Review

References

• Classification Criteria for Intermediate Uveitis. classification criteria for intermediate uveitis, non–Pars planitis type. Am J Ophthalmol. Aug 2021; 228: 159–164. doi:10.1016/j.ajo.2021.03.054.
   PubMed Web of Science ®Google Scholar
• Standardization of Uveitis Nomenclature (SUN) Working Group. Classification criteria for pars planitis. Am J Ophthalmol. 2021;228:268–274. doi:10.1016/j.ajo.2021.03.045.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005 Sep;140(3):509–516. doi:10.1016/j.ajo.2005.03.057.
   PubMed Web of Science ®Google Scholar
• Babu BM, Rathinam SR. Intermediate uveitis. Indian J Ophthalmol. 2010 Jan-Feb;58(1):21–27. doi:10.4103/0301-4738.58469.
   PubMed Web of Science ®Google Scholar
• Bonfioli AA, Damico FM, Curi AL, Orefice F. Intermediate uveitis. Semin Ophthalmol. 2005 Jul-Sep;20(3):147–154. doi:10.1080/08820530500232035.
   PubMedGoogle Scholar
• Ozdal PC, Berker N, Tugal-Tutkun I. Pars planitis: epidemiology, clinical characteristics, management and visual prognosis. J Ophthalmic Vis Res. 2015 Oct-Dec;10(4):469–480. doi:10.4103/2008-322x.176897.
   PubMedGoogle Scholar
• Lai FH, Liu DT, Lam DS. Review of intermediate uveitis. Asia-Pacific J Ophthalmol. 2013;2(6):375–387. doi:10.1097/APO.0b013e3182a2c90b.
   PubMedGoogle Scholar
• Tran VT, Auer C, Guex-Crosier Y, Pittet N, Herbort CP. Epidemiology of uveitis in Switzerland. Ocul Immunol Inflamm. 1994;2(3):169–176. doi:10.3109/09273949409057073.
   PubMedGoogle Scholar
• Van Tran T, Auer C, Guex-Crosier Y, Pittet N, Herbort CP. Epidemiological characteristics of uveitis in Switzerland. Int Ophthalmol. 1994;18(5):293–298. September 01. doi:10.1007/BF00917833.
   PubMed Web of Science ®Google Scholar
• Jones NP. The Manchester Uveitis Clinic: the first 3000 patients—epidemiology and casemix. Ocul Immunol Inflamm. 2015;23(2):118–126. doi:10.3109/09273948.2013.855799.
   PubMed Web of Science ®Google Scholar
• Mercanti A, Parolini B, Bonora A, Lequaglie Q, Tomazzoli L. Epidemiology of endogenous uveitis in North Eastern Italy. Analysis of 655 new cases. Acta Ophthalmol Scand. 2001;79(1):64–68. doi:10.1034/j.1600-0420.2001.079001064.x.
   PubMedGoogle Scholar
• Pivetti-Pezzi P, Accorinti M, La Cava M, Gisoldi RAC, Abdulaziz MA. Endogenous uveitis: an analysis of 1,417 cases. Ophthalmologica. 1996;210(4):234–238. doi:10.1159/000310715.
   PubMed Web of Science ®Google Scholar
• Kazokoglu H, Onal S, Tugal-Tutkun I, et al. Demographic and clinical features of uveitis in tertiary centers in Turkey. Ophthalmic Epidemiol. 2008;15(5):285–293. doi:10.1080/09286580802262821.
   PubMed Web of Science ®Google Scholar
• Özdal MPÇ, Yazici A, Tüfek M, Öztürk F. Epidemiology of uveitis in a referral hospital in Turkey. Turk J Med Sci. 2014;44(2):337–342. doi:10.3906/sag-1302-132.
   PubMed Web of Science ®Google Scholar
• Biswas J, Narain S, Das D, Ganesh SK. Pattern of uveitis in a referral uveitis clinic in India. Int Ophthalmol. 1996;20(4):223–228. doi:10.1007/BF00175264.
   PubMed Web of Science ®Google Scholar
• Singh R, Gupta V, Gupta A. Pattern of uveitis in a referral eye clinic in north India. Indian J Ophthalmol. 2004;52:121–125.
   PubMedGoogle Scholar
• Das D, Bhattacharjee H, Bhattacharyya PK, et al. Pattern of uveitis in North East India: a tertiary eye care center study. Indian J Ophthalmol. 2009;57(2):144. doi:10.4103/0301-4738.45506.
   PubMed Web of Science ®Google Scholar
• Dogra M, Singh R, Agarwal A, et al. Epidemiology of uveitis in a tertiary-care referral institute in North India. Ocul Immunol Inflamm. 2017;25(sup1):S46–S53. doi:10.1080/09273948.2016.1255761.
   PubMed Web of Science ®Google Scholar
• Abaño JM, Galvante PR, Siopongco P, Dans K, Lopez J. Review of epidemiology of uveitis in Asia: pattern of uveitis in a tertiary hospital in the Philippines. Ocul Immunol Inflamm. 2017;25(sup1):S75–S80. doi:10.1080/09273948.2017.1335755.
   PubMed Web of Science ®Google Scholar
• Merrill PT, Kim J, Cox TA, Betor CC, McCallum RM, Jaffe GJ. Uveitis in the southeastern United States. Curr Eye Res. 1997;16(9):865–874. doi:10.1076/ceyr.16.9.865.5048.
   PubMed Web of Science ®Google Scholar
• Bajwa A, Osmanzada D, Osmanzada S, et al. Epidemiology of uveitis in the mid-Atlantic United States. Clin Ophthalmol. 2015;9:889. doi:10.2147/OPTH.S80972.
   PubMed Web of Science ®Google Scholar
• Acharya NR, Tham VM, Esterberg E, et al. Incidence and prevalence of uveitis: results from the pacific ocular inflammation study. JAMA Ophthalmol. 2013;131(11):1405–1412. doi:10.1001/jamaophthalmol.2013.4237.
   PubMed Web of Science ®Google Scholar
• Gonzalez FD, Nascimento H, Nascimento C, Muccioli C, Belfort JR. Uveitis in São Paulo, Brazil: 1053 new patients in 15 months. Ocul Immunol Inflamm. 2017;25(3):382–387. doi:10.3109/09273948.2015.1132741.
   PubMed Web of Science ®Google Scholar
• Llorenç V, Mesquida M, Sainz de la Maza M, et al. Epidemiology of uveitis in a western urban multiethnic population. The challenge of globalization. Acta Ophthalmol. 2015;93(6):561–567. doi:10.1111/aos.12675.
   PubMed Web of Science ®Google Scholar
• Jakob E, Reuland MS, Mackensen F, et al. Uveitis subtypes in a German interdisciplinary uveitis center—analysis of 1916 patients. J Rheumatol. 2009;36(1):127–136. doi:10.3899/jrheum.080102.
   PubMed Web of Science ®Google Scholar
• Grajewski RS, Caramoy A, Frank KF, et al. Spectrum of uveitis in a German tertiary center: review of 474 consecutive patients. Ocul Immunol Inflamm. 2015;23(4):346–352. doi:10.3109/09273948.2014.1002567.
   PubMed Web of Science ®Google Scholar
• Soheilian M, Heidari K, Yazdani S, Shahsavari M, Ahmadieh H, Dehghan M. Patterns of uveitis in a tertiary eye care center in Iran. Ocul Immunol Inflamm. 2004;12(4):297–310. doi:10.1080/092739490500174.
   PubMed Web of Science ®Google Scholar
• Kianersi F, Mohammadi Z, Ghanbari H, Ghoreyshi SM, Karimzadeh H, Soheilian M. Clinical patterns of uveitis in an Iranian tertiary eye-care center. Ocul Immunol Inflamm. 2015;23(4):278–282. doi:10.3109/09273948.2014.902474.
   PubMed Web of Science ®Google Scholar
• Hosseini SM, Shoeibi N, Ebrahimi R, Ghasemi M. Patterns of uveitis at a tertiary referral center in Northeastern Iran. J Ophthalmic Vis Res. 2018;13(2):138. doi:10.4103/jovr.jovr_67_17.
   PubMed Web of Science ®Google Scholar
• Khairallah M, Yahia SB, Ladjimi A, et al. Pattern of uveitis in a referral centre in Tunisia, North Africa. Eye. 2007;21(1):33–39. January 01. doi:10.1038/sj.eye.6702111.
   PubMed Web of Science ®Google Scholar
• Hamade IH, Elkum N, Tabbara KF. Causes of uveitis at a referral center in Saudi Arabia. Ocul Immunol Inflamm. 2009;17(1):11–16. doi:10.1080/09273940802491850.
   PubMed Web of Science ®Google Scholar
• Al-Mezaine HS, Kangave D, Abu El-Asrar AM. Patterns of uveitis in patients admitted to a university hospital in Riyadh, Saudi Arabia. Ocul Immunol Inflamm. 2010;18(6):424–431. doi:10.3109/09273948.2010.502284.
   PubMed Web of Science ®Google Scholar
• Al Dhahri H, Al Rubaie K, Hemachandran S, et al. Patterns of uveitis in a university-based tertiary referral center in Riyadh, Saudi Arabia. Ocul Immunol Inflamm. 2015;23(4):311–319. doi:10.3109/09273948.2014.939197.
   PubMed Web of Science ®Google Scholar
• Silpa-Archa S, Noonpradej S, Amphornphruet A. Pattern of uveitis in a referral ophthalmology center in the central district of Thailand. Ocul Immunol Inflamm. 2015;23(4):320–328. doi:10.3109/09273948.2014.943773.
   PubMed Web of Science ®Google Scholar
• Yang P, Zhang Z, Zhou H, et al. Clinical patterns and characteristics of uveitis in a tertiary center for uveitis in China. Curr Eye Res. 2005 Nov;30(11):943–948. doi:10.1080/02713680500263606.
   PubMed Web of Science ®Google Scholar
• Bro T, Tallstedt L. Epidemiology of uveitis in a region of southern Sweden. Acta Ophthalmol. 2020;98(1):32–35. doi:10.1111/aos.14130.
   PubMed Web of Science ®Google Scholar
• Win MZ, Win T, Myint S, Shwe T, Sandar H. Epidemiology of uveitis in a tertiary eye center in Myanmar. Ocul Immunol Inflamm. 2017;25(sup1):S69–S74. doi:10.3109/09273948.2015.1133839.
   PubMed Web of Science ®Google Scholar
• Hart CT, Zhu EY, Crock C, Rogers SL, Lim LL. Epidemiology of uveitis in urban Australia. Clin Exp Ophthalmol. 2019;47:733–740.
   PubMed Web of Science ®Google Scholar
• Shirahama S, Kaburaki T, Nakahara H, et al. Epidemiology of uveitis (2013–2015) and changes in the patterns of uveitis (2004–2015) in the central Tokyo area: a retrospective study. BMC Ophthalmol. 2018;18(1):1–8. doi:10.1186/s12886-018-0871-6.
   PubMedGoogle Scholar
• Siak J, Kumaradas M, Chee S-P. The pattern of uveitis in Sri Lanka. Ocul Immunol Inflamm. 2017;25(sup1):S63–S68. doi:10.1080/09273948.2017.1313991.
   PubMed Web of Science ®Google Scholar
• Siak J, Jansen A, Waduthantri S, Teoh C-S, Jap A, Chee S-P. The pattern of uveitis among Chinese, Malays, and Indians in Singapore. Ocul Immunol Inflamm. 2017;25(sup1):S81–S93. doi:10.1080/09273948.2016.1188968.
   PubMed Web of Science ®Google Scholar
• Cunningham ET Jr. Uveitis in children. Ocul Immunol Inflamm. 2000 Dec;8(4):251–261. doi:10.1076/ocii.8.4.251.6459.
   PubMed Web of Science ®Google Scholar
• BenEzra D. Uveitis in children and adolescents. Br J Ophthalmol. 2005 Apr;89(4):444–448. doi:10.1136/bjo.2004.050609.
   PubMed Web of Science ®Google Scholar
• Zierhut M, Michels H, Stübiger N, Besch D, Deuter C, Heiligenhaus A. Uveitis in children. Int Ophthalmol Clin. 2005;45(2):135–156. doi:10.1097/01.iio.0000155903.87679.c2.
   PubMedGoogle Scholar
• Ness T, Boehringer D, Heinzelmann S. Intermediate uveitis: pattern of etiology, complications, treatment and outcome in a tertiary academic center. Orphanet J Rare Dis. 12(1):81. April 27 2017. doi:10.1186/s13023-017-0638-9.
   PubMedGoogle Scholar
• Nikkhah H, Ramezani A, Ahmadieh H, et al. Childhood pars planitis; clinical features and outcomes. J Ophthalmic Vis Res. Oct 2011;6(4):249–254.
   PubMedGoogle Scholar
• Raja SC, Jabs DA, Dunn JP, et al. Pars planitis: clinical features and class II HLA associations. Ophthalmology. 1999 Mar;106(3):594–599. doi:10.1016/S0161-6420(99)90122-7.
   PubMed Web of Science ®Google Scholar
• Berker N, Sen E, Elgin U, Atilgan CU, Dursun E, Yilmazbas P. Analysis of clinical features and visual outcomes of pars planitis. Int Ophthalmol. 2018 Apr;38(2):727–736. doi:10.1007/s10792-017-0526-2.
   PubMed Web of Science ®Google Scholar
• Soylu M, Ozdemir G, Anli A. Pediatric uveitis in southern Turkey. Ocul Immunol Inflamm. 1997 Sep;5(3):197–202. doi:10.3109/09273949709116894.
   PubMed Web of Science ®Google Scholar
• Smith JA, Mackensen F, Sen HN, et al. Epidemiology and course of disease in childhood uveitis. Ophthalmology. 2009 Aug;116(8):1544–1551. doi:10.1016/j.ophtha.2009.05.002.
   PubMed Web of Science ®Google Scholar
• Ozdal PC, Sen E, Yazici A, Ozturk F. Patterns of childhood-onset uveitis in a referral center in Turkey. J Ophthalmic Inflamm Infect. 2012 Mar;2(1):13–19. doi:10.1007/s12348-011-0044-8.
   PubMedGoogle Scholar
• Niederer RL, Sharief L, Bar A, Lightman SL, Tomkins-Netzer O. Predictors of long-term visual outcome in intermediate uveitis. Ophthalmology. 2017;124(3):393–398. March 01. doi:10.1016/j.ophtha.2016.11.013.
   PubMed Web of Science ®Google Scholar
• Kalinina Ayuso V, ten Cate Ha, van den Does P, Rothova A, de Boer JH. Young age as a risk factor for complicated course and visual outcome in intermediate uveitis in children. Br J Ophthalmol. 2011 May;95(5):646–651. doi:10.1136/bjo.2010.184267.
   PubMed Web of Science ®Google Scholar
• Heinz C, Schoonbrood S, Heiligenhaus A. Intermediate uveitis in children and young adults: differences in clinical course, associations and visual outcome. British J Ophthalmol. 2014;98(8):1107–1111. doi:10.1136/bjophthalmol-2013-304589.
   PubMed Web of Science ®Google Scholar
• Sancho L, Kramer M, Koriat A, Eiger-Moscovich M, Sharon Y, Amer R. Complications in intermediate uveitis: prevalence, time of onset, and effects on vision in short-term and long-term follow-Up. Ocul Immunol Inflamm. 2019;27(3):447–455. April 03. doi:10.1080/09273948.2017.1420203.
   PubMed Web of Science ®Google Scholar
• Paroli MP, Abicca I, Sapia A, Bruschi S, Pezzi PP. Intermediate uveitis: comparison between childhood-onset and adult-onset disease. Eur J Ophthalmol. 2014;24(1):94–100. doi:10.5301/ejo.5000336.
   PubMed Web of Science ®Google Scholar
• Rathinam SR, Namperumalsamy P. Global variation and pattern changes in epidemiology of uveitis. Indian J Ophthalmol. 2007 May-Jun;55(3):173–183. doi:10.4103/0301-4738.31936.
   PubMedGoogle Scholar
• Nölle B, Eckardt C. Cellular phenotype of vitreous cells in intermediate uveitis. In: Intermediate Uveitis. Vol. 23. Karger Publishers; 1992:145–149.
   Google Scholar
• Davis JL, Solomon D, Nussenblatt RB, Palestine AG, Chan CC. Immunocytochemical staining of vitreous cells. Indications, techniques, and results. Ophthalmology. 1992 February;99(2):250–256. doi:10.1016/s0161-6420(92)31984-0.
   PubMed Web of Science ®Google Scholar
• Wetzig RP, Chan C, Nussenblatt RB, Palestine A, Mazur D, Mittal K. Clinical and immunopathological studies of pars planitis in a family. British J Ophthalmol. 1988;72(1):5–10. doi:10.1136/bjo.72.1.5.
   PubMed Web of Science ®Google Scholar
• Pederson JE, Kenyon KR, Green WR, Maumenee AE. Pathology of pars planitis. Am J Ophthalmol. 1978 Dec;86(6):762–774. doi:10.1016/0002-9394(78)90118-6.
   PubMed Web of Science ®Google Scholar
• Caspi RR. A look at autoimmunity and inflammation in the eye. J Clin Invest. 2010 Sep;120(9):3073–3083. doi:10.1172/jci42440.
   PubMed Web of Science ®Google Scholar
• Bansal S, Barathi VA, Iwata D, Agrawal R. Experimental autoimmune uveitis and other animal models of uveitis: an update. Indian J Ophthalmol. 2015 Mar;63(3):211–218. doi:10.4103/0301-4738.156914.
   PubMed Web of Science ®Google Scholar
• Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol. 2005;123(5):634–641. doi:10.1001/archopht.123.5.634.
   PubMedGoogle Scholar
• Maruyama K, Inaba T, Sugita S, et al. Comprehensive analysis of vitreous specimens for uveitis classification: a prospective multicentre observational study. BMJ Open. November 16 2017;7(11):e014549. doi:10.1136/bmjopen-2016-014549.
   PubMed Web of Science ®Google Scholar
• Murphy CC. Systemic CD4+ T cell phenotype and activation status in intermediate uveitis. British J Ophthalmol. 2004;88(3):412–416. doi:10.1136/bjo.2003.028506.
   PubMed Web of Science ®Google Scholar
• Lindner E, Weger M, Ardjomand N, Renner W, El-Shabrawi Y. Associations of independent IL2RA gene variants with intermediate uveitis. PLoS One. 2015;10(7):e0130737. doi:10.1371/journal.pone.0130737.
   PubMed Web of Science ®Google Scholar
• Lindner E, Weger M, Steinwender G, et al. IL2RA gene polymorphism rs2104286 A>G seen in multiple sclerosis is associated with intermediate uveitis: possible parallel pathways? Invest Ophthalmol Vis Sci. October 21 2011;52(11):8295–8299. doi:10.1167/iovs.11-8163.
   PubMed Web of Science ®Google Scholar
• Ewald L, Beate LW, Stephanie S, Wilfried R, Yosuf El S. Analysis of a functional IL-6 gene polymorphism in HLAB27 associated and intermediate uveitis gives new insight in disease pathogenesis and commonality with other autoimmune diseases. J Immunol Res. 2015;2015:174062. doi:10.1155/2015/174062.
   PubMed Web of Science ®Google Scholar
• Tang WM, Pulido JS, Eckels DD, Han DP, Mieler WF, Pierce K. The association of HLA-DR15 and intermediate uveitis. Am J Ophthalmol. 1997 Jan;123(1):70–75. doi:10.1016/s0002-9394(14)70994-8.
   PubMed Web of Science ®Google Scholar
• Arellanes-Garcia L, Navarro-Lopez L, Recillas-Gispert C. Pars planitis in the Mexican Mestizo population: ocular findings, treatment, and visual outcome. Ocul Immunol Inflamm. 2003 Mar;11(1):53–60. doi:10.1076/ocii.11.1.53.15583.
   PubMed Web of Science ®Google Scholar
• Martin T, Weber M, Schmitt C, et al. Association of intermediate uveitis with HLA-A28: definition of a new systemic syndrome? Graefes Arch Clin Exp Ophthalmol. 1995 May;233(5):269–274. doi:10.1007/bf00177648.
   PubMed Web of Science ®Google Scholar
• Bertrand PJ, Jamilloux Y, Ecochard R, et al. Uveitis: autoimmunity … and beyond. Autoimmun Rev. 2019 Sep;18(9):102351. doi:10.1016/j.autrev.2019.102351.
   PubMed Web of Science ®Google Scholar
• Lee AG. Familial pars planitis. Ophthalmic Genet. 1995 Mar;16(1):17–19. doi:10.3109/13816819509057849.
   PubMed Web of Science ®Google Scholar
• Biswas J, Raghavendran SR, Vijaya R. Intermediate uveitis of pars planitis type in identical twins. Report of a case. Int Ophthalmol. 1998;22(5):275–277. doi:10.1023/a:1006327721918.
   PubMed Web of Science ®Google Scholar
• Duinkerke-Eerola KU, Pinckers A, Cruysberg JRM. Pars planitis in father and son. Ophthalmic Paediatr Genet. 1990;11(4):305–308. doi:10.3109/13816819009015718.
   Google Scholar
• El Latif E A, Abdelhalim AS, Montasser AS, et al. Pattern of intermediate uveitis in an Egyptian cohort.Ocul Immunol Inflamm. 28(3):524–531. Epub.Apr 2 2020. doi:10.1080/09273948.2019.1668429.
   PubMed Web of Science ®Google Scholar
• Paroli MP, Spinucci G, Monte R, Pesci FR, Abicca I, Pivetti Pezzi P. Intermediate uveitis in a pediatric Italian population. Ocul Immunol Inflamm. 2011;19(5):321–326. doi:10.3109/09273948.2011.603878.
   PubMed Web of Science ®Google Scholar
• Arellanes-García L, Navarro-López P, Concha-Del Río LE, Unzueta-Medina JA. Idiopathic intermediate uveitis in childhood. Int Ophthalmol Clin. 2008;48(3):61–74. Summer. doi:10.1097/IIO.0b013e31817d84af.
   PubMedGoogle Scholar
• Davis JL, Madow B, Cornett J, et al. Scale for photographic grading of vitreous haze in uveitis. Am J Ophthalmol. 2010;150(5):637–641.e1. November 01. doi:10.1016/j.ajo.2010.05.036.
   PubMed Web of Science ®Google Scholar
• Madow B, Galor A, Feuer WJ, Altaweel MM, Davis JL. Validation of a photographic vitreous haze grading technique for clinical trials in uveitis. Am J Ophthalmol. 2011;152(2):170–176.e1. August 01. doi:10.1016/j.ajo.2011.01.058.
   PubMed Web of Science ®Google Scholar
• Keane PA, Karampelas M, Sim DA, et al. Objective measurement of vitreous inflammation using optical coherence tomography. Ophthalmology. 2014;121(9):1706–1714. September 01. doi:10.1016/j.ophtha.2014.03.006.
   PubMed Web of Science ®Google Scholar
• Keane PA, Balaskas K, Sim DA, et al. Automated analysis of vitreous inflammation using spectral-domain optical coherence tomography. Trans Vision Sci Technol. 2015;4(5): 4-4. doi:10.1167/tvst.4.5.4.
   PubMed Web of Science ®Google Scholar
• Coric D, Ometto G, Montesano G, et al. Objective quantification of vitreous haze on optical coherence tomography scans: no evidence for relationship between uveitis and inflammation in multiple sclerosis. Eur J Neurol. 2020;27(1):144–e3.doi:10.1111/ene.14048.
   PubMed Web of Science ®Google Scholar
• Laovirojjanakul W, Acharya N, Gonzales JA. Ultra-widefield fluorescein angiography in intermediate uveitis. Ocul Immunol Inflamm. 2019;27(3):356–361. doi:10.1080/09273948.2017.1371764.
   PubMed Web of Science ®Google Scholar
• Davis JL. Intermediate Uveitis. In: Albert D, Miller J, Azar D, Young LH, eds. Albert and Jakobiec’s Principles and Practice of Ophthalmology. Springer International Publishing; 2020:1–32.
   Google Scholar
• Group SoUNW. Classification criteria for pars planitis. Am J Ophthalmol. 2021;228:268–274. doi:10.1016/j.ajo.2021.03.045.
   PubMed Web of Science ®Google Scholar
• Przeździecka-Dołyk J, Węgrzyn A, Turno-Kręcicka A, Misiuk-Hojło M. Immunopathogenic background of pars planitis. Arch Immunol Ther Exp (Warsz). 2016 Apr;64(2):127–137. doi:10.1007/s00005-015-0361-y.
   PubMed Web of Science ®Google Scholar
• El-Asrar AM A, Geboes K. An immunohistochemical study of the ‘snowbank’ in a case of pars planiti. Ocul Immunol Inflamm. 2002 Jun;10(2):117–123. doi:10.1076/ocii.10.2.117.13980.
   PubMed Web of Science ®Google Scholar
• Khairallah M, Hmidi K, Attia S, et al. Clinical characteristics of intermediate uveitis in Tunisian patients. Int Ophthalmol. 2010 Oct;30(5):531–537. doi:10.1007/s10792-010-9352-5.
   PubMedGoogle Scholar
• Boer J, Berendschot TTJM, Pvd D, Rothova A. Long-term follow-up of intermediate uveitis in children. Am J Ophthalmol. 2006;141(4):616–616.e7. April 01. doi:10.1016/j.ajo.2005.09.035.
   PubMed Web of Science ®Google Scholar
• Rotsos TG. Cystoid macular edema. Clin Ophthalmol. 2008 Dec;2(4):919–930. doi:10.2147/opth.s4033.
   PubMedGoogle Scholar
• Guex-Crosier Y. The pathogenesis and clinical presentation of macular edema in inflammatory diseases. Doc Ophthalmol. 1999;97(3–4):297–309. doi:10.1023/a:1002130005227.
   PubMed Web of Science ®Google Scholar
• Tranos PG, Wickremasinghe SS, Stangos NT, Topouzis F, Tsinopoulos I, Pavesio CE. Macular edema. Surv Ophthalmol. 2004 Sep-Oct;49(5):470–490. doi:10.1016/j.survophthal.2004.06.002.
   PubMed Web of Science ®Google Scholar
• Navarrete A, Koriat A, Amer R. Implications of pars planitis-associated cystoid macular edema on visual outcome and management in children. Graefes Arch Clin Exp Ophthalmol. 2020;258(8):1803–1811. August 01. doi:10.1007/s00417-020-04696-7.
   PubMed Web of Science ®Google Scholar
• Parchand S, Tandan M, Gupta V, Gupta A. Intermediate uveitis in Indian population. J Ophthalmic Inflamm Infect. 2011 Jun;1(2):65–70. 2011 Feb 23. doi:10.1007/s12348-011-0020-3. Epub.
   PubMedGoogle Scholar
• Gupta V, Al-Dhibi HA, Arevalo JF. Retinal imaging in uveitis. Saudi J Ophthalmol. 2014;28(2):95–103. April 01. doi:10.1016/j.sjopt.2014.02.008.
   PubMedGoogle Scholar
• Markomichelakis NN, Halkiadakis I, Pantelia E, et al. Patterns of macular edema in patients with uveitis: qualitative and quantitative assessment using optical coherence tomography. Ophthalmology. 2004;111(5):946–953. May 01. doi:10.1016/j.ophtha.2003.08.037.
   PubMed Web of Science ®Google Scholar
• Simonazzi B, Balaskas K, Guex-Crosier Y. A cross-sectional study of submacular thickening in intermediate uveitis and determination of treatment threshold. BMC Ophthalmol. 2016;16(1):59. May 18. doi:10.1186/s12886-016-0230-4.
   PubMedGoogle Scholar
• Laovirojjanakul W, Acharya N, Gonzales JA. Ultra-widefield fluorescein angiography in intermediate uveitis. Ocul Immunol Inflamm. 2019;27(3):356–361. April 03. doi:10.1080/09273948.2017.1371764.
   PubMed Web of Science ®Google Scholar
• Engelhard SB, Patel V, Reddy AK. Intermediate uveitis, posterior uveitis, and panuveitis in the Mid-Atlantic USA. Clin Ophthalmol. 2015;9:1549–1555. doi:10.2147/opth.S89428.
   PubMed Web of Science ®Google Scholar
• Neri P, Azuara-Blanco A, Forrester JV. Incidence of glaucoma in patients with uveitis. J Glaucoma. 2004 Dec;13(6):461–465. doi:10.1097/01.ijg.0000146391.77618.d0.
   PubMed Web of Science ®Google Scholar
• Herbert HM, Viswanathan A, Jackson H, Lightman SL. Risk factors for elevated intraocular pressure in uveitis. J Glaucoma. 2004 Apr;13(2):96–99. doi:10.1097/00061198-200404000-00003.
   PubMed Web of Science ®Google Scholar
• Siddique SS, Suelves AM, Baheti U, Foster CS. Glaucoma and Uveitis. Surv Ophthalmol. 2013;58(1):1–10. January 01. doi:10.1016/j.survophthal.2012.04.006.
   PubMed Web of Science ®Google Scholar
• Tanner V, Kanski JJ, Frith PA. Posterior sub-Tenon’s triamcinolone injections in the treatment of uveitis. Eye. 1998;12(4):679–685. July 01. doi:10.1038/eye.1998.168.
   PubMedGoogle Scholar
• Liu X, Li Y, Zhang Y, et al. Comparison of intraocular pressure elevation after anterior versus posterior subtenon triamcinolone acetonide acetate injection: a retrospective study. Retina. 2012 Oct;32(9):1838–1843. doi:10.1097/IAE.0b013e31824fd384.
   PubMed Web of Science ®Google Scholar
• Chew EY, Glassman AR, Beck RW, et al. Ocular side effects associated with peribulbar injections of triamcinolone acetonide for diabetic macular edema. Retina. 2011 Feb;31(2):284–289. doi:10.1097/IAE.0b013e3181f049a8.
   PubMed Web of Science ®Google Scholar
• Iwao K, Inatani M, Kawaji T, Koga T, Mawatari Y, Tanihara H. Frequency and risk factors for intraocular pressure elevation after posterior sub-Tenon capsule triamcinolone acetonide injection. J Glaucoma. 2007 Mar;16(2):251–256. doi:10.1097/IJG.0b013e31802d696f.
   PubMed Web of Science ®Google Scholar
• Jain R, Ferrante P, Reddy GT, Lightman S. Clinical features and visual outcome of intermediate uveitis in children. Clin Exp Ophthalmol. 2005;33(1):22–25. doi:10.1111/j.1442-9071.2005.00938.x.
   PubMed Web of Science ®Google Scholar
• Jancevski M, Foster CS. Cataracts and uveitis. Curr Opin Ophthalmol. 2010;21(1):10–14. doi:10.1097/ICU.0b013e328332f575.
   PubMed Web of Science ®Google Scholar
• Blum-Hareuveni T, Seguin-Greenstein S, Kramer M, et al. Risk factors for the development of cataract in children with uveitis. Am J Ophthalmol. 2017;177:139–143. May 01. doi:10.1016/j.ajo.2017.02.023.
   PubMed Web of Science ®Google Scholar
• Donaldson MJ, Pulido JS, Herman DC, Diehl N, Hodge D. Pars planitis: a 20-year study of incidence, clinical features, and outcomes. Am J Ophthalmol. 2007;144(6):812–817. e2. doi:10.1016/j.ajo.2007.08.023.
   PubMed Web of Science ®Google Scholar
• Arellanes-García L, Navarro-López LP, Recillas-Gispert C. Pars planitis in the Mexican Mestizo population: ocular findings, treatment, and visual outcome. Ocul Immunol Inflamm. 2003;11:53–60.
   PubMed Web of Science ®Google Scholar
• Mehta S, Linton MM, Kempen JH. Outcomes of cataract surgery in patients with uveitis: a systematic review and meta-analysis. Am J Ophthalmol. 2014;158(4):676–692.e7. October 01. doi:10.1016/j.ajo.2014.06.018.
   PubMed Web of Science ®Google Scholar
• Ganesh SK, Babu K, Biswas J. Phacoemulsification with intraocular lens implantation in cases of pars planitis. J Cataract Refract Surg. 2004 Oct;30(10):2072–2076. doi:10.1016/j.jcrs.2004.02.090.
   PubMed Web of Science ®Google Scholar
• Nemet AY, Raz J, Sachs D, et al. Primary intraocular lens implantation in pediatric uveitis: a comparison of 2 populations. Arch Ophthalmol. 2007;125(3):354–360. doi:10.1001/archopht.125.3.354.
   PubMedGoogle Scholar
• Nicholson BP, Zhou M, Rostamizadeh M, et al. Epidemiology of epiretinal membrane in a large cohort of patients with uveitis. Ophthalmology. 2014 Dec;121(12):2393–2398. doi:10.1016/j.ophtha.2014.06.015.
   PubMed Web of Science ®Google Scholar
• Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Sugar EA. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol. 2010 Apr;149(4):550–561.e10. doi:10.1016/j.ajo.2009.11.019.
   PubMed Web of Science ®Google Scholar
• Sheybani A, Harocopos GJ, Rao PK. Immunohistochemical study of epiretinal membranes in patients with uveitis. J Ophthalmic Inflamm Infect. 2012 Dec;2(4):243–248. doi:10.1007/s12348-012-0074-x.
   PubMedGoogle Scholar
• Amer R, Nalcı H, Yalçındağ N. Exudative retinal detachment. Surv Ophthalmol. 2017;62(6):723–769. November 01. doi:10.1016/j.survophthal.2017.05.001.
   PubMed Web of Science ®Google Scholar
• Jalil A, Dhawahir-Scala FE, Jones NP. Nonprogressive tractional inferior retinal elevation in intermediate uveitis. Ocul Immunol Inflamm. 2010 Jan;18(1):60–63. doi:10.3109/09273940903315784.
   PubMed Web of Science ®Google Scholar
• Pollack AL, McDonald HR, Johnson RN, et al. Peripheral retinoschisis and exudative retinal detachment in pars planitis. Retina. 2002 Dec;22(6):719–724. doi:10.1097/00006982-200212000-00006.
   PubMed Web of Science ®Google Scholar
• Lauer AK, Smith JR, Robertson JE, Rosenbaum JT. Vitreous hemorrhage is a common complication of pediatric pars planitis. Ophthalmology. 2002;109(1):95–98. doi:10.1016/S0161-6420(01)00866-1.
   PubMed Web of Science ®Google Scholar
• Pichi F, Neri P, Agarwal A, et al. Vasoproliferative tumors in intermediate uveitis. Retina. 2020 Sep;40(9):1765–1773. doi:10.1097/iae.0000000000002656.
   PubMed Web of Science ®Google Scholar
• Garcia-Arumi J, Distefano LN, Fonollosa A, Quijano C, Corcostegui B. Management of Vision-Threatening Complications of Vasoproliferative Tumors of the Retina. Ophthalmic Res. 2015;54(1):34–40. doi:10.1159/000430955.
   PubMed Web of Science ®Google Scholar
• Kump LI, Cervantes-Castañeda RA, Androudi SN, Foster CS. Analysis of pediatric uveitis cases at a tertiary referral center. Ophthalmology. 2005;112(7):1287–1292. July 01. doi:10.1016/j.ophtha.2005.01.044.
   PubMed Web of Science ®Google Scholar
• Giles CL. Pediatric intermediate uveitis. J Pediatr Ophthalmol Strabismus. 1989 May-Jun;26(3):136–139. doi:10.3928/0191-3913-19890501-10.
   PubMedGoogle Scholar
• Tomkins-Netzer O, Talat L, Bar A, et al. Long-term clinical outcome and causes of vision loss in patients with uveitis. Ophthalmology. 2014 Dec;121(12):2387–2392. doi:10.1016/j.ophtha.2014.07.007.
   PubMed Web of Science ®Google Scholar
• Chang JH-M, Wakefield D. Uveitis: a global perspective. Ocul Immunol Inflamm. 2002;10(4):263–279. doi:10.1076/ocii.10.4.263.15592.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Johns CJ. Ocular involvement in chronic sarcoidosis. Am J Ophthalmol. 1986;102(3):297–301. doi:10.1016/0002-9394(86)90001-2.
   PubMed Web of Science ®Google Scholar
• Standardization of Uveitis Nomenclature (SUN) Working Group. Classification criteria for sarcoidosis-associated uveitis. Am J Ophthalmol. 2021;228:220–230. doi:10.1016/j.ajo.2021.03.047.
   PubMed Web of Science ®Google Scholar
• Standardization of Uveitis Nomenclature (SUN) Working Group. Classification criteria for multiple sclerosis-associated intermediate uveitis. Am J Ophthalmol. 2021;228:72–79. doi:10.1016/j.ajo.2021.03.044.
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162–173. doi:10.1016/s1474-4422(17)30470-2.
   PubMed Web of Science ®Google Scholar
• Dodds EM, Lowder CY, Meisler DM. Posterior segment inflammation in HLA-B27+ acute anterior uveitis: clinical characteristics. Ocul Immunol Inflamm. 1999;7(2):85–92. January 01. doi:10.1076/ocii.7.2.85.4015.
   PubMed Web of Science ®Google Scholar
• Tay-Kearney M-L, Schwam BL, Lowder C, et al. Clinical features and associated systemic diseases of HLA-B27 uveitis. Am J Ophthalmol. 1996;121(1):47–56. January 01. doi:10.1016/S0002-9394(14)70533-1.
   PubMed Web of Science ®Google Scholar
• Braakenburg AMD, de Valk HW, de Boer J, Rothova A. Human leukocyte antigen-B27–associated uveitis: long-term follow-up and gender differences. Am J Ophthalmol. 2008;145(3):472–479. March 01. doi:10.1016/j.ajo.2007.11.009.
   PubMed Web of Science ®Google Scholar
• Power WJ. Outcomes in anterior uveitis associated with the HLA-B27 haplotype. Ophthalmology. 1998;105(9):1646–1651. September 01. doi:10.1016/S0161-6420(98)99033-9.
   PubMed Web of Science ®Google Scholar
• Pakzad-Vaezi K, Pepple KL. Tubulointerstitial nephritis and uveitis. Curr Opin Ophthalmol. 2017 Nov;28(6):629–635. doi:10.1097/icu.0000000000000421.
   PubMed Web of Science ®Google Scholar
• Standardization of Uveitis Nomenclature (SUN) Working Group. Classification criteria for tubulointerstitial nephritis with uveitis syndrome. Am J Ophthalmol. 2021;228:255–261. doi:10.1016/j.ajo.2021.03.041.
   PubMed Web of Science ®Google Scholar
• Jones NP. The Manchester Uveitis Clinic: the first 3000 patients–epidemiology and casemix. Ocul Immunol Inflamm. 2015 Apr;23(2):118–126. doi:10.3109/09273948.2013.855799.
   PubMed Web of Science ®Google Scholar
• Agrawal R, Gunasekeran DV, Grant R, et al. Clinical features and outcomes of patients with tubercular uveitis treated with antitubercular therapy in the collaborative ocular tuberculosis study (COTS)–1. JAMA Ophthalmol. 2017;135(12):1318–1327.doi:10.1001/jamaophthalmol.2017.4485.
   PubMed Web of Science ®Google Scholar
• Mi H, Ho SL, Lim WK, Wong EP, Teoh SC. Trends in patterns of intermediate uveitis in a tertiary institution in Singapore. PLoS One. 2014;9(3):e91533. doi:10.1371/journal.pone.0091533.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Belfort R, Bodaghi B, et al. Classification criteria for syphilitic uveitis. Am J Ophthalmol. 2021;228:182–191. August 01. doi:10.1016/j.ajo.2021.03.039.
   PubMed Web of Science ®Google Scholar
• Bernard A, Seve P, Abukhashabh A, et al. Lyme-associated uveitis: clinical spectrum and review of literature. Eur J Ophthalmol. 2020 Sep;30(5):874–885. doi:10.1177/1120672119856943.
   PubMed Web of Science ®Google Scholar
• Breeveld J, Rothova A, Kuiper H. Intermediate uveitis and Lyme borreliosis. Br J Ophthalmol. 1992 Mar;76(3):181–182. doi:10.1136/bjo.76.3.181.
   PubMed Web of Science ®Google Scholar
• Kwon JW, Sim Y, Jee D. Association between intermediate uveitis and toxocariasis in the Korean population. Medicine (Baltimore). 2017 Feb;96(5):e5829. doi:10.1097/md.0000000000005829.
   PubMed Web of Science ®Google Scholar
• Wensing B, Mochizuki M, De Boer JH. Clinical characteristics of herpes simplex virus associated anterior uveitis. Ocul Immunol Inflamm. 2018;26(3):333–337. April 03. doi:10.1080/09273948.2017.1420806.
   PubMed Web of Science ®Google Scholar
• Wensing B, de Groot-mijnes JDF, Rothova A. Necrotizing and nonnecrotizing variants of herpetic uveitis with posterior segment involvement. Arch Ophthalmol. 2011;129(4):403–408. doi:10.1001/archophthalmol.2010.313.
   PubMedGoogle Scholar
• Faia LJ, Chan -C-C. Primary intraocular lymphoma. Arch Pathol Lab Med. 2009;133(8):1228–1232. doi:10.5858/133.8.1228.
   PubMed Web of Science ®Google Scholar
• Coupland SE, Damato B. Understanding intraocular lymphomas. Clin Exp Ophthalmol. 2008;36(6):564–578. doi:10.1111/j.1442-9071.2008.01843.x.
   PubMed Web of Science ®Google Scholar
• Reichstein D. Primary vitreoretinal lymphoma: an update on pathogenesis, diagnosis and treatment. Curr Opin Ophthalmol. 2016;27(3):177–184. doi:10.1097/ICU.0000000000000255.
   PubMed Web of Science ®Google Scholar
• Sagoo MS, Mehta H, Swampillai AJ, et al. Primary intraocular lymphoma. Surv Ophthalmol. 2014;59(5):503–516. September 01. doi:10.1016/j.survophthal.2013.12.001.
   PubMed Web of Science ®Google Scholar
• Chan -C-C, Whitcup SM, Solomon D, Nussenblatt RB. Interleukin-10 in the vitreous of patients with primary intraocular lymphoma. Am J Ophthalmol. 1995;120(5):671–673. November 01. doi:10.1016/S0002-9394(14)72217-2.
   PubMed Web of Science ®Google Scholar
• Soheilian M, Mirbabai F, Shahsavari M, Parvin M, Manieei F. Metastatic cutaneous melanoma to the vitreous cavity masquerading as intermediate uveitis. Eur J Ophthalmol. 2002;12(4):324–327. doi:10.1177/112067210201200413.
   PubMed Web of Science ®Google Scholar
• Barisani-Asenbauer T, Maca SM, Mejdoubi L, Emminger W, Machold K, Auer H. Uveitis- a rare disease often associated with systemic diseases and infections- a systematic review of 2619 patients. Orphanet J Rare Dis. Aug 29 2012;7:57. doi:10.1186/1750-1172-7-57.
   PubMed Web of Science ®Google Scholar
• Poindron V, Camuset G, Krencker D, et al. Intermediate uveitis, an ophthalmological manifestation of systemic disease. J Fr Ophtalmol. 2013 Apr;36(4):331–335. doi:10.1016/j.jfo.2012.05.007.
   PubMed Web of Science ®Google Scholar
• Bernard A, Seve P, Abukhashabh A, et al. Lyme-associated uveitis: clinical spectrum and review of literature. Eur J Ophthalmol. June 26 2019;1120672119856943. doi:10.1177/1120672119856943.
   Web of Science ®Google Scholar
• Petrushkin H, Kidd D, Pavesio C. Intermediate uveitis and multiple sclerosis: to scan or not to scan. British J Ophthalmol. 2015;99(12):1591–1593. doi:10.1136/bjophthalmol-2015-307269.
   PubMed Web of Science ®Google Scholar
• Garcia-Feijoo J, Martin-Carbajo M, JMBd C, Garcia-Sanchez J. Ultrasound biomicroscopy in pars planitis. Am J Ophthalmol. 1996;121(2):214–215. February 01. doi:10.1016/S0002-9394(14)70590-2.
   PubMed Web of Science ®Google Scholar
• Häring G, Nölle B, Wiechens B. Ultrasound biomicroscopic imaging in intermediate uveitis. British J Ophthalmol. 1998;82(6):625–629. doi:10.1136/bjo.82.6.625.
   PubMed Web of Science ®Google Scholar
• Trichonas G, Kaiser PK. Optical coherence tomography imaging of macular oedema. British J Ophthalmol. 2014;98(Suppl 2):ii24–ii29. doi:10.1136/bjophthalmol-2014-305305.
   PubMed Web of Science ®Google Scholar
• Géhl Z, Kulcsár K, Kiss HJM, Németh J, Maneschg OA, Resch MD. Retinal and choroidal thickness measurements using spectral domain optical coherence tomography in anterior and intermediate uveitis. BMC Ophthalmol. 2014;14(1):103. August 30. doi:10.1186/1471-2415-14-103.
   PubMedGoogle Scholar
• Doro D, Manfrè A, Deligianni V, Secchi AG. Combined 50- and 20-MHz Frequency ultrasound imaging in intermediate uveitis. Am J Ophthalmol. 2006;141(5):953–955. May 01. doi:10.1016/j.ajo.2005.11.048.
   PubMed Web of Science ®Google Scholar
• Choudhry N, Duker JS, Freund KB, et al. Classification and guidelines for widefield imaging: recommendations from the international widefield imaging study group. Ophthalmol. Retina. 2019 Oct;3(10):843–849. doi:10.1016/j.oret.2019.05.007.
   PubMedGoogle Scholar
• Hong BK, Khanamiri HN, Rao NA. Role of ultra-widefield fluorescein angiography in the management of uveitis. Can J Ophthalmol. 2013;48(6):489–493. doi:10.1016/j.jcjo.2013.05.009.
   PubMed Web of Science ®Google Scholar
• Kaines A, Tsui I, Sarraf D, Schwartz S. The use of ultra wide field fluorescein angiography in evaluation and management of uveitis. In: Seminars in Ophthalmology. Vol. 24, No. 1. Taylor & Francis; 2009:19–24.
   Google Scholar
• Tsui I, Kaines A, Schwartz S. Patterns of periphlebitis in intermediate uveitis using ultra wide field fluorescein angiography. Semin Ophthalmol. 2009 Jan-Feb;24(1):29–33. doi:10.1080/08820530802520186.
   PubMed Web of Science ®Google Scholar
• Wintergerst MWM, Pfau M, Müller PL, et al. Optical coherence tomography angiography in intermediate uveitis. Am J Ophthalmol. 2018;194:35–45. October 01. doi:10.1016/j.ajo.2018.06.023.
   PubMed Web of Science ®Google Scholar
• Tian M, Tappeiner C, Zinkernagel MS, Wolf S, Munk MR. Swept-source optical coherence tomography angiography reveals vascular changes in intermediate uveitis. Acta Ophthalmol. 2019;97(5):e785–e791. doi:10.1111/aos.14024.
   PubMed Web of Science ®Google Scholar
• Li CQ, Cho AA, Edward NJ, Edward DP, Fajardo RG, Mafee MF. Magnetic resonance imaging of uveitis. Neuroradiology. 2015 Aug;57(8):825–832. doi:10.1007/s00234-015-1531-7.
   PubMed Web of Science ®Google Scholar
• Hadjadj J, Dechartres A, Chapron T, et al. Relevance of diagnostic investigations in patients with uveitis: retrospective cohort study on 300 patients. Autoimmun Rev. 2017;16(5):504–511. May 01. doi:10.1016/j.autrev.2017.03.006.
   PubMed Web of Science ®Google Scholar
• Chirpaz N, Kerever S, Gavoille A, et al. Relevance of brain MRI in patients with uveitis: retrospective cohort on 402 patients. Ocul Immunol Inflamm. Apr 7 2021;1–7. doi:10.1080/09273948.2020.1870145.
   Web of Science ®Google Scholar
• Prieto JF, Dios E, Gutierrez JM, Mayo A, Calonge M, Herreras JM. Pars planitis: epidemiology, treatment, and association with multiple sclerosis. Ocul Immunol Inflamm. 2001 Jun;9(2):93–102. doi:10.1076/ocii.9.2.93.3975.
   PubMed Web of Science ®Google Scholar
• Kaplan HJ. Surgical treatment of intermediate uveitis. Dev Ophthalmol. 1992;23:185–189. doi:10.1159/000429650.
   PubMedGoogle Scholar
• Foster CS, Kothari S, Anesi SD, et al. The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management. Surv Ophthalmol. 2016;61(1):1–17. January 01. doi:10.1016/j.survophthal.2015.07.001.
   PubMed Web of Science ®Google Scholar
• Al-Janabi A, El Nokrashy A, Sharief L, Nagendran V, Lightman S, Tomkins-Netzer O. Long-term outcomes of treatment with biological agents in eyes with refractory, active, noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology. 2020;127(3):410–416. March 01. doi:10.1016/j.ophtha.2019.08.031.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Adán A, Brézin AP, et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018;125(7):1075–1087. July 01. doi:10.1016/j.ophtha.2017.12.039.
   PubMed Web of Science ®Google Scholar
• Thomas AS. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics. Curr Opin Ophthalmol. 2019;30(3):138–150. doi:10.1097/ICU.0000000000000562.
   PubMed Web of Science ®Google Scholar
• McCartney HJ, Drysdale IO, Gornall AG, Basu PK. An autoradiographic study of the penetration of subconjunctivally injected hydrocortisone into the normal and inflamed rabbit eye. Invest Ophthalmol. Jun 1965;4:297–302.
   PubMedGoogle Scholar
• Hyndiuk RA. Radioactive depot-corticosteroid penetration into monkey ocular tissue: I. retrobulbar and systemic administration. Arch Ophthalmol. 1968;80(4):499–503. doi:10.1001/archopht.1968.00980050501019.
   PubMedGoogle Scholar
• Helm CJ, Holland GN. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol. 1995;120(1):55–64. July 01. doi:10.1016/S0002-9394(14)73759-6.
   PubMed Web of Science ®Google Scholar
• Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology. 2001;108(4):765–772. April 01. doi:10.1016/S0161-6420(00)00658-8.
   PubMed Web of Science ®Google Scholar
• Kwak HW. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol. 1992 Feb;110(2):259–266. doi:10.1001/archopht.1992.01080140115038.
   PubMed Web of Science ®Google Scholar
• Akduman L, Kolker AE, Black DL, Del Priore LV, Kaplan HJ. Treatment of persistent glaucoma secondary to periocular corticosteroids. Am J Ophthalmol. 1996;122(2):275–277. August 01. doi:10.1016/S0002-9394(14)72027-6.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four–week results of a multicenter randomized clinical study. Ophthalmology. 2006;113(6):1020–1027. doi:10.1016/j.ophtha.2006.02.021.
   PubMed Web of Science ®Google Scholar
• Malclès A, Dot C, Voirin N, et al. Safety of intravitreal dexamethasone implant (Ozurdex): the SAFODEX study. Incidence and risk factors of ocular hypertension. Retina. 2017;37(7):1352–1359. doi:10.1097/IAE.0000000000001369.
   PubMed Web of Science ®Google Scholar
• Palla S, Biswas J, Nagesha CK. Efficacy of Ozurdex implant in treatment of noninfectious intermediate uveitis. Indian J Ophthalmol. 2015 Oct;63(10):767–770. doi:10.4103/0301-4738.171505.
   PubMed Web of Science ®Google Scholar
• Sella R, Oray M, Friling R, Umar L, Tugal-Tutkun I, Kramer M. Dexamethasone intravitreal implant (Ozurdex®) for pediatric uveitis. Graefes Arch Clin Exp Ophthalmol. 2015;253(10):1777–1782. October 01. doi:10.1007/s00417-015-3124-x.
   PubMed Web of Science ®Google Scholar
• Arcinue CA, Cerón OM, Foster CS. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther. 2013;29(5):501–507. doi:10.1089/jop.2012.0180.
   PubMed Web of Science ®Google Scholar
• Thorne JE, Sugar EA, Holbrook JT, et al. Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the periocular vs. intravitreal corticosteroids for uveitic macular edema (POINT) trial. Ophthalmology. 2019 Feb;126(2):283–295. doi:10.1016/j.ophtha.2018.08.021.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Lin P, Keenan RT, Ashton P, Skalak C, Stinnett SS. Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: two-year results. Ophthalmology. 2016;123(9):1940–1948. doi:10.1016/j.ophtha.2016.05.025.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Foster CS, Pavesio CE, Paggiarino DA, Riedel GE. Effect of an injectable fluocinolone acetonide insert on recurrence rates in chronic noninfectious uveitis affecting the posterior segment: twelve-month results. Ophthalmology. 2019;126(4):601–610. April 01. doi:10.1016/j.ophtha.2018.10.033.
   PubMed Web of Science ®Google Scholar
• Venkatesh P, Abhas Z, Garg S, Vohra R. Prospective optical coherence tomographic evaluation of the efficacy of oral and posterior subtenon corticosteroids in patients with intermediate uveitis. Graefes Arch Clin Exp Ophthalmol. 2007;245(1):59–67. January 01. doi:10.1007/s00417-006-0378-3.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000 Oct;130(4):492–513. doi:10.1016/s0002-9394(00)00659-0.
   PubMed Web of Science ®Google Scholar
• Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011 Oct;118(10):1916–1926. doi:10.1016/j.ophtha.2011.07.027.
   PubMed Web of Science ®Google Scholar
• Kempen JH, Altaweel MM, Drye LT, et al. Benefits of systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, and panuveitis: fifty-four-month results of the multicenter uveitis steroid treatment (MUST) trial and follow-up study. Ophthalmology. 2015 Oct;122(10):1967–1975. doi:10.1016/j.ophtha.2015.06.042.
   PubMed Web of Science ®Google Scholar
• Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group. Quality of life and risks associated with systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, or panuveitis: fifty-four-month results of the multicenter uveitis steroid treatment trial and follow-up study. Ophthalmology. 2015;122(10):1976–1986. doi:10.1016/j.ophtha.2015.06.043.
   PubMed Web of Science ®Google Scholar
• Larson T, Nussenblatt RB, Sen HN. Emerging drugs for uveitis. Expert Opin Emerg Drugs. 2011 Jun;16(2):309–322. doi:10.1517/14728214.2011.537824.
   PubMed Web of Science ®Google Scholar
• Kempen JH, Daniel E, Gangaputra S, et al. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic immunosuppressive therapy for eye diseases (SITE) cohort study. Ophthalmic Epidemiol. 2008;15(1):47–55. January 01. doi:10.1080/09286580701585892.
   PubMed Web of Science ®Google Scholar
• Malik AR. The use of low dose methotrexate in children with chronic anterior and intermediate uveitis. Br J Ophthalmol. 2005 Jul;89(7):806–808. doi:10.1136/bjo.2004.054239.
   PubMed Web of Science ®Google Scholar
• Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001;108(6):1134–1139. June 01. doi:10.1016/S0161-6420(01)00576-0.
   PubMed Web of Science ®Google Scholar
• Sahin O, Ziaei A. The role of methotrexate in resolving ocular inflammation after specific therapy for presumed latent syphilitic uveitis and presumed tuberculosis-related uveitis. Retina. 2014;34(7):1451–1459. doi:10.1097/IAE.0000000000000080.
   PubMed Web of Science ®Google Scholar
• Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148(4):500–509.e2. October 01. doi:10.1016/j.ajo.2009.05.008.
   PubMed Web of Science ®Google Scholar
• Rathinam SR, Gonzales JA, Thundikandy R, et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA. 2019;322(10):936–945.doi:10.1001/jama.2019.12618.
   PubMed Web of Science ®Google Scholar
• Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2008;115(10):1826–1832. doi:10.1016/j.ophtha.2008.04.026.
   PubMed Web of Science ®Google Scholar
• Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology. 2008;115(8):1416–1421.e1. August 01. doi:10.1016/j.ophtha.2007.12.011.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC, Stevens JG, Mellow SD, Green SB. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol. 1991;112(2):138–146. doi:10.1016/S0002-9394(14)76692-9.
   PubMed Web of Science ®Google Scholar
• Lee RWJ, Greenwood R, Taylor H, et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology. 2012;119(6):1223–1230. June 01. doi:10.1016/j.ophtha.2011.12.030.
   PubMed Web of Science ®Google Scholar
• Hogan AC, McAvoy CE, Dick AD, Lee RW. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology. 2007;114(5):1000–1006. e4. doi:10.1016/j.ophtha.2007.01.026.
   PubMed Web of Science ®Google Scholar
• Tedesco D, Haragsim L. Cyclosporine: a review. J Transplant. 2012;2012:1–7. doi:10.1155/2012/230386.
   Google Scholar
• Deray G, Benhmida M, Le Hoang P, et al. Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis. Ann Intern Med. 1992;117(7):578–583. doi:10.7326/0003-4819-117-7-578.
   PubMed Web of Science ®Google Scholar
• Mihatsch M, Kyo M, Morozumi K, Yamaguchi Y, Nickeleit V, Ryffel B. The side-effects of cyclosporine-A and tacrolimus. Clin Nephrol. 1998;49:356–363.
   PubMed Web of Science ®Google Scholar
• Shanmuganathan VA, Casely EM, Raj D, et al. The efficacy of sirolimus in the treatment of patients with refractory uveitis. British J Ophthalmol. 2005;89(6):666–669. doi:10.1136/bjo.2004.048199.
   PubMed Web of Science ®Google Scholar
• Ibrahim MA, Sepah YJ, Watters A, et al. One-year outcomes of the save study: sirolimus as a therapeutic approach for uVEitis. Transl Vis Sci Technol. 2015 Mar;4(2):4. doi:10.1167/tvst.4.2.4.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Clark WL, et al. Intravitreal Sirolimus for noninfectious uveitis: a phase iii sirolimus study assessing double-masked uveitis treatment (SAKURA). Ophthalmology. 2016 Nov;123(11):2413–2423. doi:10.1016/j.ophtha.2016.07.029.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943.doi:10.1056/NEJMoa1509852.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–1192. September 17. doi:10.1016/S0140-6736(16)31339-3.
   PubMed Web of Science ®Google Scholar
• Kruh JN, Yang P, Suelves AM, Foster CS. Infliximab for the treatment of refractory noninfectious uveitis: a study of 88 patients with long-term follow-up. Ophthalmology. 2014 January;121(1):358–364. doi:10.1016/j.ophtha.2013.07.019.
   PubMed Web of Science ®Google Scholar
• Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006 Feb;113(2):308–314. doi:10.1016/j.ophtha.2005.09.037.
   PubMed Web of Science ®Google Scholar
• Maleki A, Sahawneh HF, Ma L, Meese H, He Y, Foster CS. Infliximab therapy in patients with noninfectious intermediate uveitis resistant to conventional immunomodulatory therapy. Retina. 2017;37(5):836–843. doi:10.1097/IAE.0000000000001269.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Rigante D, et al. Comparative efficacy between Adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. Clin Rheumatol. 2019;38(2):407–415. February 01. doi:10.1007/s10067-018-4228-6.
   PubMed Web of Science ®Google Scholar
• Schaap-Fogler M, Amer R, Friling R, Priel E, Kramer M. Anti-TNF-α agents for refractory cystoid macular edema associated with noninfectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2014;252(4):633–640. April 01. doi:10.1007/s00417-013-2552-8.
   PubMed Web of Science ®Google Scholar
• Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol. 2003;121(4):437–440. doi:10.1001/archopht.121.4.437.
   PubMed Web of Science ®Google Scholar
• Mackensen F, Jakob E, Springer C, et al. Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial. Am J Ophthalmol. 2013;156(3):478–486. e1. doi:10.1016/j.ajo.2013.05.002.
   PubMed Web of Science ®Google Scholar
• Agrawal R, Betzler BK, Testi I, et al. The collaborative ocular tuberculosis study (Cots)-1: a multinational review of 447 patients with tubercular intermediate uveitis and panuveitis. Ocul Immunol Inflamm. Nov 17 2020;1–11. doi:10.1080/09273948.2020.1808226.
   Web of Science ®Google Scholar
• Ang M, Hedayatfar A, Wong W, Chee SP. Duration of anti-tubercular therapy in uveitis associated with latent tuberculosis: a case-control study. Br J Ophthalmol. Mar 2012;96(3):332–336. Epub 2011 Jun 30. doi:10.1136/bjophthalmol-2011-300209.
   PubMed Web of Science ®Google Scholar
• Babu K, Satish V, Prakash O, Subbakrishna DK, Murthy KR. Role of the Mantoux test and treatment with antitubercular therapy in a South Indian patient population of presumed intraocular tuberculosis. Ocul Immunol Inflamm. 2009 Sep-Oct;17(5):307–311. doi:10.3109/09273940902999349.
   PubMed Web of Science ®Google Scholar
• Agrawal R, Gonzalez-Lopez JJ, Nobre-Cardoso J, et al. Predictive factors for treatment failure in patients with presumed ocular tuberculosis in an area of low endemic prevalence. Br J Ophthalmol. Mar 2016;100(3):348–355. Epub 2015 Jul 17. doi:10.1136/bjophthalmol-2014-306474.
   PubMed Web of Science ®Google Scholar
• Agrawal R, Testi I, Bodaghi B, et al. Collaborative ocular tuberculosis study consensus guidelines on the management of tubercular uveitis-report 2: guidelines for initiating antitubercular therapy in anterior uveitis, intermediate uveitis, panuveitis, and retinal vasculitis. Ophthalmology. 2021 Feb;128(2):277–287. doi:10.1016/j.ophtha.2020.06.052.
   PubMed Web of Science ®Google Scholar
• Montero JA, Ruiz-Moreno JM. Cryotherapy and laser for intermediate uveitis. In: Surgical Management of Inflammatory Eye Disease. Berlin, Heidelberg: Springer; 2008:47–57.
   Google Scholar
• Sızmaz S, Güngör SG, Bayar SA, Yılmaz G, Akkoyun I. Laser photocoagulation in intermediate uveitis associated with retinoschisis. Ocul Immunol Inflamm. 2012 Oct;20(5):372–374. doi:10.3109/09273948.2012.704116.
   PubMed Web of Science ®Google Scholar
• Nagiel A, Lalane RA, Sadda SR, Schwartz SD. Ultra-widefield fundus imaging: a review of clinical applications and future trends. Retina. 2016;36(4):660–678. doi:10.1097/IAE.0000000000000937.
   PubMed Web of Science ®Google Scholar
• Josephberg RG, Kanter ED, Jaffee RM. A fluorescein angiographic study of patients with pars planitis and peripheral exudation (snowbanking) before and after cryopexy. Ophthalmology. 1994 Jul;101(7):1262–1266. doi:10.1016/s0161-6420(13)31726-6.
   PubMed Web of Science ®Google Scholar
• Devenyi RG, Mieler WF, Lambrou FH, Will BR, Aaberg TM. Cryopexy of the vitreous base in the management of peripheral uveitis. Am J Ophthalmol. 106(2):135–138. Aug 15 1988. doi:10.1016/0002-9394(88)90824-0.
   PubMed Web of Science ®Google Scholar
• Heimann H, Bornfeld N, Vij O, et al. Vasoproliferative tumours of the retina. Br J Ophthalmol. 2000;84(10):1162–1169. doi:10.1136/bjo.84.10.1162.
   PubMed Web of Science ®Google Scholar
• Damato B. Vasoproliferative retinal tumour. Br J Ophthalmol. 2006 Apr;90(4):399–400. doi:10.1136/bjo.2005.086066.
   PubMed Web of Science ®Google Scholar
• Jaccoma EH. Cryotherapy causes extensive breakdown of the blood-retinal barrier: a Comparison With Argon Laser Photocoagulation. Arch Ophthalmol. 1985;103(11):1728–1730. doi:10.1001/archopht.1985.01050110124039.
   PubMedGoogle Scholar
• Kempen JH, Gewaily DY, Newcomb CW, et al. Remission of Intermediate Uveitis: incidence and Predictive Factors. Am J Ophthalmol. Apr 2016; 164:110–7.e2. doi:10.1016/j.ajo.2015.12.034.
   PubMed Web of Science ®Google Scholar
• Giuliari GP, Chang PY, Thakuria P, Hinkle DM, Foster CS. Pars plana vitrectomy in the management of paediatric uveitis: the Massachusetts eye research and surgery Institution experience. Eye. 2010;24(1):7–13. January 01. doi:10.1038/eye.2009.294.
   PubMed Web of Science ®Google Scholar
• Stavrou P, Baltatzis S, Letko E, Samson CM, Christen W, Foster CS. Pars plana vitrectomy in patients with intermediate uveitis. Ocul Immunol Inflamm. 2001;9(3):141–151. January 01. doi:10.1076/ocii.9.3.141.3965.
   PubMed Web of Science ®Google Scholar
• Becker M, Davis J. Vitrectomy in the Treatment of Uveitis. Am J Ophthalmol. 2005;140(6):1096–1105. December 01. doi:10.1016/j.ajo.2005.07.017.
   PubMed Web of Science ®Google Scholar
• Wentworth BA, Freitas-Neto CA, Foster CS. Management of pediatric uveitis. F1000Prime Rep. 2014;6:41. doi:10.12703/p6-41.
   PubMedGoogle Scholar
• Patel CC, Mandava N, Oliver SCN, Braverman R, Quiroz-Mercado H, Olson JL. Treatment of intractable posterior uveitis in pediatric patients with the fluocinolone acetonide intravitreal implant (Retisert). RETINA. 2012;32(3):537–542. doi:10.1097/IAE.0b013e31822058bb.
   PubMed Web of Science ®Google Scholar
• Bratton ML, He Y-G, Weakley DR. Dexamethasone intravitreal implant (Ozurdex) for the treatment of pediatric uveitis. J AAPOS. 2014;18(2):110–113. doi:10.1016/j.jaapos.2013.11.014.
   PubMed Web of Science ®Google Scholar
• Kothari S, Foster CS, Pistilli M, et al. The risk of intraocular pressure elevation in pediatric noninfectious uveitis. Ophthalmology. 2015 Oct;122(10):1987–2001. doi:10.1016/j.ophtha.2015.06.041.
   PubMed Web of Science ®Google Scholar
• Nuyen B, Weinreb RN, Robbins SL. Steroid-induced glaucoma in the pediatric population. J AAPOS. 2017;21(1):1–6. February 01. doi:10.1016/j.jaapos.2016.09.026.
   PubMed Web of Science ®Google Scholar
• Simonini G, Paudyal P, Jones GT, Cimaz R, Macfarlane GJ. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology (Oxford). 2013 May;52(5):825–831. doi:10.1093/rheumatology/kes186.
   PubMed Web of Science ®Google Scholar
• Vazquez-Cobian LB, Flynn T, Lehman TJA. Adalimumab therapy for childhood uveitis. J Pediatr. 2006;149(4):572–575. October 01. doi:10.1016/j.jpeds.2006.04.058.
   PubMed Web of Science ®Google Scholar
• Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. British J Ophthalmol. 2007;91(3):319–324.doi:10.1136/bjo.2006.103721.
   PubMed Web of Science ®Google Scholar
• Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of Adalimumab versus infliximab. Arthritis Care Res (Hoboken). 2011;63(4):612–618.doi:10.1002/acr.20404.
   PubMed Web of Science ®Google Scholar
• Lin P, Loh AR, Margolis TP, Acharya NR. Cigarette smoking as a risk factor for uveitis. Ophthalmology. 2010;117(3):585–590. March 01. doi:10.1016/j.ophtha.2009.08.011.
   PubMed Web of Science ®Google Scholar
• Thorne JE, Daniel E, Jabs DA, Kedhar SR, Peters GB, Dunn JP. Smoking as a risk factor for cystoid macular edema complicating intermediate uveitis. Am J Ophthalmol. 2008;145(5):841–846.e2. May 01. doi:10.1016/j.ajo.2007.12.032.
   PubMed Web of Science ®Google Scholar
• Roesel M, Ruttig A, Schumacher C, Heinz C, Heiligenhaus A. Smoking complicates the course of non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2011;249(6):903–907. June 01. doi:10.1007/s00417-010-1597-1.
   PubMed Web of Science ®Google Scholar